Plummer Elizabeth Ruth
Northern Institute for Cancer Research, Paul O'Gorman Building, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Curr Opin Pharmacol. 2006 Aug;6(4):364-8. doi: 10.1016/j.coph.2006.02.004. Epub 2006 Jun 5.
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.
在临床前研究中，作为一种化疗或放疗增敏策略，DNA修复酶聚（ADP - 核糖）聚合酶-1（PARP-1）的抑制作用已得到广泛研究。最近有证据表明，PARP抑制剂在某些携带DNA修复缺陷的罕见遗传性癌症中可能作为单一药物发挥作用。因此，强效PARP-1抑制剂在过去三年已进入癌症患者的早期临床试验，人们急切期待这些试验的最终结果。
